Abiopharma

🔍 Munshi Amit (Executive)

Company: Inhibikase Therapeutics, Inc. (IKT)

Report Date: 2025-02-21

Detailed Transactions and Holdings:

• Acquired 57,265 shares of Common Stock (Direct)
  Date: 2025-02-21 | Code: A | equity_swap_involved: false | shares_owned_after: 57,265.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-02-21 | Code: H | nature_of_ownership: By Amit Munshi Revocable Trust | shares_owned_after: 365,000.00

Footnotes:

• F1: Represents shares of common stock issued to the Reporting Person as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. ("CorHepta") on February 21, 2025 (the "Closing Date") by the Issuer, pursuant to the Agreement and Plan of Merger and Reorganization by and among the Issuer, Project IKT Merger Sub, Inc., CorHepta, and Preston S. Klassen, solely in his capacity as sellers' representative. Of these, 9,544 shares vested on the Closing Date, 28,632 shares shall vest on the first anniversary of the Closing Date. 25% of the remaining 19,089 shares will vest upon achievement of a certain milestone and 75% will vest on the first anniversary of the Closing Date, subject to the Reporting Person's continued service through such date; provided that, if the milestone is not achieved by the first anniversary of the Closing Date, all 19,089 shares shall be forfeited.